Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field
Authors:
- H. L. McLeodHMH. L. McLeod
Open Access
- 1 November 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 41 (11) , 1273-1279
Abstract
Objectives. To review the fundamental concepts of pharmacogenetics and analyse how the broad principles of this rapidly emerging field may influence the treatment of rheumatic disease in future. Methods. The names of common rheumatic drugs and the terms ‘pharmacogenetics’, ‘pharmacogenomics' and ‘genetic polymorphism’ were used as keywords to search the Medline and Current Contents databases. General review articles on pharmacogenetics were also examined. Results. Pharmacogenetics is the study of how genetic differences influence the variability in drug toxicity and efficacy. Although the principles of pharmacogenetics have been known for several decades, recent technological advances have hastened the possibility of direct clinical applications. Most studies so far have been phenotypic analyses, but genotyping is now readily available for many polymorphisms. There are several examples pertinent to rheumatology that illustrate the important principles and foretell the usefulness of pharmacogenetics in individualizing therapy. However, further studies are needed. Conclusions. Because traditional pharmacotherapy in rheumatology has been empirical and because of the slow acting nature of many anti‐rheumatic medications, the risk of significant side‐effects and the increasing armamentarium of drugs available, pharmacogenetics is particularly relevant to rheumatology. There are many scientific and non‐scientific concerns that should be addressed in future studies.Keywords
This publication has 36 references indexed in Scilit:
- The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patientsArthritis & Rheumatism, 2001
- Pharmacogenomics: Hope or Hype?International Journal of Cardiology, 2000
- DNA chip technology ante portasJournal of Molecular Medicine, 1999
- Methotrexate in rheumatoid arthritis: An updatewith focus on mechanisms involved in toxicitySeminars in Arthritis and Rheumatism, 1998
- Genetic Polymorphism of Drug Metabolizing Enzymes. Implications for Toxicity of Drugs and Other Xenobiotics1997
- The hypoalgesic effect of tramadol in relation to CYP2D6*Clinical Pharmacology & Therapeutics, 1996
- The Role of Genetic Variation in Thiopurine Methyltransferase Activity and the Efficacy and/or Side Effects of Azathioprine Therapy in Dermatologic PatientsArchives of Dermatology, 1995
- Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosusArthritis & Rheumatism, 1986